Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sanyuan Rupixiao Gel Patch is a topical Traditional Chinese Medicine (TCM) formulation developed by Shanxi Fengyuan Pharmaceutical Co., Ltd. for the treatment of breast hyperplasia. It is specifically indicated for patients presenting with the Qi stagnation and blood stasis syndrome, a common diagnostic category in TCM associated with breast pain and glandular nodules. The drug is formulated as a gel patch (cataplasm), which facilitates the transdermal delivery of active botanical constituents directly to the affected breast tissue. This localized delivery system is intended to improve patient compliance and reduce systemic side effects compared to oral Rupixiao formulations. The product is currently undergoing Phase II clinical evaluation in China to assess its efficacy in reducing breast pain and nodule size.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sanyuan Rupixiao Gel Patch.